India’s pharmaceutical exports to the UK are projected to reach $981.16 million by FY2026-27 under the new India-UK trade agreement. The pact removes tariffs on generic medicines, aiming to enhance competitiveness and strengthen supply chain ties. Investors should note that drug formulations currently dominate these shipments, accounting for nearly 90% of the total export value.
India’s pharmaceutical sector is expected to see a boost in export volumes to the United Kingdom following the implementation of the India-UK Comprehensive Economic and Trade Agreement. According to projections by the Pharmaceuticals Export Promotion Council of India, Pharmexcil, exports are forecast to grow by 8.66% to reach $981.16 million in the 2026-27 fiscal year. This follows a previous fiscal year where exports stood at $902.96 million.
Impact of Tariff Removal on Generic Drugs
The trade agreement eliminates tariffs on a wide range of goods, including pharmaceuticals. For Indian companies, this removal of trade barriers is designed to make generic medicines more cost-competitive when competing against other international suppliers in the British market. The reduction in costs is expected to support better margins for exporters who were previously burdened by tariff structures. With drug formulations and biological products making up 89.54% of current exports to the UK, companies with a strong portfolio in finished dosage forms are likely to be the primary beneficiaries of this improved access.
Strategic Importance of the UK Market
The United Kingdom remains India’s largest pharmaceutical export destination in Europe and its third-largest globally. The agreement is also intended to improve regulatory cooperation, which historically has been a key factor for Indian firms navigating the stringent quality standards required by European health regulators. Aside from finished formulations, exports of Active Pharmaceutical Ingredients and bulk drugs reached $72.66 million in the previous fiscal year, indicating a broader base of demand beyond just retail-ready medicines.
Monitorables for Investors
While the trade agreement provides a framework for growth, actual benefit to individual companies will depend on their ability to meet the regulatory requirements of the UK market and maintain supply chain efficiency. Investors should track future export data to see if the growth trend holds, particularly for companies with high exposure to the European market. Additionally, monitoring updates on manufacturing partnerships and research collaborations between Indian firms and UK-based entities will provide insight into how companies are leveraging this trade pact to diversify their revenue streams. The sustainability of this growth will also depend on the stability of global raw material prices and the continued demand for cost-effective generic alternatives within the UK’s healthcare system.